New drug IRL757 passes first safety check in healthy humans
NCT ID NCT06493045
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug, IRL757, in 82 healthy adults aged 18-55. Participants received either single or multiple doses of the drug or a placebo. The study focused on side effects and how the drug moves through the body, not on treating any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IRL757
- What this could lead to
- If safe, this could pave the way for future studies to see if IRL757 might treat a disease.
- What could go wrong
- This is a very early, first-in-human trial in healthy people, not patients. It only checks safety, not whether the drug works for any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NOT DETERMINED are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CTC Clinical Trial Consultants AB, Uppsala University Hospital
Uppsala, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.